HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, Gee AP, Wang RF, Hayes TG.
Sonpavde G, et al. Among authors: wang hy, wang rf, wang m.
Invest New Drugs. 2014 Apr;32(2):235-242. doi: 10.1007/s10637-013-9960-9. Epub 2013 Apr 23.
Invest New Drugs. 2014.
PMID: 23609828
Free PMC article.
Clinical Trial.